RECRUITING

Comprehensive Assessment of Cancer Theranostic Response

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.

Official Title

Comprehensive Assessment of Cancer Theranostic Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics

Quick Facts

Study Start:2024-12-02
Study Completion:2026-02-26
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06815354

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older and willing and able to provide informed consent.
  2. * Diagnosis of metastatic prostate cancer.
  3. * Planned to start 177Lu-PSMA (Pluvicto).
  4. * Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
  5. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.
  1. * Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.

Contacts and Locations

Study Contact

Dona Alberti
CONTACT
608-268-9684
dona.alberti@aiq-solutions.com

Study Locations (Sites)

Weill Medical College of Cornell
New York, New York, 10065
United States
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: AIQ Solutions

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-02
Study Completion Date2026-02-26

Study Record Updates

Study Start Date2024-12-02
Study Completion Date2026-02-26

Terms related to this study

Keywords Provided by Researchers

  • Prostate Cancer
  • Theranostics
  • PET/CT

Additional Relevant MeSH Terms

  • Prostate Cancer